A two-stage case-control association study of PADI2 with schizophrenia

Yuichiro Watanabe, Ayako Nunokawa, Naoshi Kaneko, Tadao Arinami, Hiroshi Ujike, Toshiya Inada, Nakao Iwata, Hiroshi Kunugi, Masanari Itokawa, Takeshi Otowa, Norio Ozaki, Toshiyuki Someya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peptidylarginine deiminases (PADIs), five isoforms of which have been identified, catalyze the conversion of arginine residues to citrulline residues in proteins. Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis. Such a progressive neurodegenerative process could be involved in the etiology and/or course of schizophrenia, and PADI2 may be a candidate gene for schizophrenia. To assess whether PADI2 has a role in vulnerability to schizophrenia, we conducted a two-stage case-control association study in Japanese individuals. In a screening population of 534 patients and 559 control individuals, we examined eight single-nucleotide polymorphisms (SNPs) including four haplotype tag SNPs and four coding SNPs in PADI2. There was a potential association of a synonymous SNP in exon 7 with schizophrenia. However, we could not replicate this association in a confirmatory population of 2126 patients and 2228 control individuals. The results of this study suggest that PADI2 does not contribute to genetic susceptibility to schizophrenia.

Original languageEnglish
Pages (from-to)430-432
Number of pages3
JournalJournal of Human Genetics
Volume54
Issue number7
DOIs
Publication statusPublished - 01-07-2009

Fingerprint

Case-Control Studies
Schizophrenia
Single Nucleotide Polymorphism
Alzheimer Disease
Citrulline
Genetic Predisposition to Disease
Neurodegenerative Diseases
Haplotypes
Nervous System
Transcriptional Activation
Population
Multiple Sclerosis
Arginine
Exons
Protein Isoforms
Genes
Proteins

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Cite this

Watanabe, Y., Nunokawa, A., Kaneko, N., Arinami, T., Ujike, H., Inada, T., ... Someya, T. (2009). A two-stage case-control association study of PADI2 with schizophrenia. Journal of Human Genetics, 54(7), 430-432. https://doi.org/10.1038/jhg.2009.52
Watanabe, Yuichiro ; Nunokawa, Ayako ; Kaneko, Naoshi ; Arinami, Tadao ; Ujike, Hiroshi ; Inada, Toshiya ; Iwata, Nakao ; Kunugi, Hiroshi ; Itokawa, Masanari ; Otowa, Takeshi ; Ozaki, Norio ; Someya, Toshiyuki. / A two-stage case-control association study of PADI2 with schizophrenia. In: Journal of Human Genetics. 2009 ; Vol. 54, No. 7. pp. 430-432.
@article{30e95f5e7dde4c0292af27255c0f060e,
title = "A two-stage case-control association study of PADI2 with schizophrenia",
abstract = "Peptidylarginine deiminases (PADIs), five isoforms of which have been identified, catalyze the conversion of arginine residues to citrulline residues in proteins. Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis. Such a progressive neurodegenerative process could be involved in the etiology and/or course of schizophrenia, and PADI2 may be a candidate gene for schizophrenia. To assess whether PADI2 has a role in vulnerability to schizophrenia, we conducted a two-stage case-control association study in Japanese individuals. In a screening population of 534 patients and 559 control individuals, we examined eight single-nucleotide polymorphisms (SNPs) including four haplotype tag SNPs and four coding SNPs in PADI2. There was a potential association of a synonymous SNP in exon 7 with schizophrenia. However, we could not replicate this association in a confirmatory population of 2126 patients and 2228 control individuals. The results of this study suggest that PADI2 does not contribute to genetic susceptibility to schizophrenia.",
author = "Yuichiro Watanabe and Ayako Nunokawa and Naoshi Kaneko and Tadao Arinami and Hiroshi Ujike and Toshiya Inada and Nakao Iwata and Hiroshi Kunugi and Masanari Itokawa and Takeshi Otowa and Norio Ozaki and Toshiyuki Someya",
year = "2009",
month = "7",
day = "1",
doi = "10.1038/jhg.2009.52",
language = "English",
volume = "54",
pages = "430--432",
journal = "Journal of Human Genetics",
issn = "1434-5161",
publisher = "Nature Publishing Group",
number = "7",

}

Watanabe, Y, Nunokawa, A, Kaneko, N, Arinami, T, Ujike, H, Inada, T, Iwata, N, Kunugi, H, Itokawa, M, Otowa, T, Ozaki, N & Someya, T 2009, 'A two-stage case-control association study of PADI2 with schizophrenia', Journal of Human Genetics, vol. 54, no. 7, pp. 430-432. https://doi.org/10.1038/jhg.2009.52

A two-stage case-control association study of PADI2 with schizophrenia. / Watanabe, Yuichiro; Nunokawa, Ayako; Kaneko, Naoshi; Arinami, Tadao; Ujike, Hiroshi; Inada, Toshiya; Iwata, Nakao; Kunugi, Hiroshi; Itokawa, Masanari; Otowa, Takeshi; Ozaki, Norio; Someya, Toshiyuki.

In: Journal of Human Genetics, Vol. 54, No. 7, 01.07.2009, p. 430-432.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A two-stage case-control association study of PADI2 with schizophrenia

AU - Watanabe, Yuichiro

AU - Nunokawa, Ayako

AU - Kaneko, Naoshi

AU - Arinami, Tadao

AU - Ujike, Hiroshi

AU - Inada, Toshiya

AU - Iwata, Nakao

AU - Kunugi, Hiroshi

AU - Itokawa, Masanari

AU - Otowa, Takeshi

AU - Ozaki, Norio

AU - Someya, Toshiyuki

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Peptidylarginine deiminases (PADIs), five isoforms of which have been identified, catalyze the conversion of arginine residues to citrulline residues in proteins. Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis. Such a progressive neurodegenerative process could be involved in the etiology and/or course of schizophrenia, and PADI2 may be a candidate gene for schizophrenia. To assess whether PADI2 has a role in vulnerability to schizophrenia, we conducted a two-stage case-control association study in Japanese individuals. In a screening population of 534 patients and 559 control individuals, we examined eight single-nucleotide polymorphisms (SNPs) including four haplotype tag SNPs and four coding SNPs in PADI2. There was a potential association of a synonymous SNP in exon 7 with schizophrenia. However, we could not replicate this association in a confirmatory population of 2126 patients and 2228 control individuals. The results of this study suggest that PADI2 does not contribute to genetic susceptibility to schizophrenia.

AB - Peptidylarginine deiminases (PADIs), five isoforms of which have been identified, catalyze the conversion of arginine residues to citrulline residues in proteins. Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis. Such a progressive neurodegenerative process could be involved in the etiology and/or course of schizophrenia, and PADI2 may be a candidate gene for schizophrenia. To assess whether PADI2 has a role in vulnerability to schizophrenia, we conducted a two-stage case-control association study in Japanese individuals. In a screening population of 534 patients and 559 control individuals, we examined eight single-nucleotide polymorphisms (SNPs) including four haplotype tag SNPs and four coding SNPs in PADI2. There was a potential association of a synonymous SNP in exon 7 with schizophrenia. However, we could not replicate this association in a confirmatory population of 2126 patients and 2228 control individuals. The results of this study suggest that PADI2 does not contribute to genetic susceptibility to schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=68449085006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449085006&partnerID=8YFLogxK

U2 - 10.1038/jhg.2009.52

DO - 10.1038/jhg.2009.52

M3 - Article

C2 - 19478818

AN - SCOPUS:68449085006

VL - 54

SP - 430

EP - 432

JO - Journal of Human Genetics

JF - Journal of Human Genetics

SN - 1434-5161

IS - 7

ER -

Watanabe Y, Nunokawa A, Kaneko N, Arinami T, Ujike H, Inada T et al. A two-stage case-control association study of PADI2 with schizophrenia. Journal of Human Genetics. 2009 Jul 1;54(7):430-432. https://doi.org/10.1038/jhg.2009.52